TSE:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free AEZS Stock Alerts C$10.76 -0.73 (-6.35%) (As of 05/8/2024 ET) Add Compare Share Share Today's RangeC$10.76▼C$11.4750-Day RangeC$2.46▼C$11.4952-Week RangeC$7.64▼C$16.92Volume2,102 shsAverage Volume539 shsMarket CapitalizationC$52.29 millionP/E RatioN/ADividend Yield2.79%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Aeterna Zentaris alerts: Email Address Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About Aeterna Zentaris Stock (TSE:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesMay 3, 2024 | americanbankingnews.comAeterna Zentaris (TSE:AEZS) Stock Price Down 2.1%May 1, 2024 | theglobeandmail.comAEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)May 8, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 31, 2024 | theglobeandmail.comAEterna Zentaris: Top 25 Undervalued Toronto Stock Exchange Stocks (AEZS)March 28, 2024 | markets.businessinsider.comCourt Approves Ceapro-Aeterna Merger - Quick FactsMarch 28, 2024 | finance.yahoo.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisFebruary 21, 2024 | benzinga.comAEterna Zentaris Stock (NASDAQ:AEZS) Dividends: History, Yield and DatesFebruary 15, 2024 | msn.comAeterna Zentaris files to sell 2.53M warrantsMay 8, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 15, 2024 | finance.yahoo.comAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproJanuary 22, 2024 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc flat on Monday (AEZS)December 14, 2023 | tmcnet.comAEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to ShareholdersDecember 14, 2023 | marketwatch.comAeterna Zentaris, Ceapro to CombineDecember 14, 2023 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AEZSDecember 14, 2023 | markets.businessinsider.comAeterna Zentaris Enters Into Merger Agreement With CeaproDecember 14, 2023 | msn.comAeterna Zentaris and Ceapro to merge in all-stock dealOctober 20, 2023 | theglobeandmail.comAEterna Zentaris: Top 10 Undervalued Growth Stocks on TSX (AEZS)August 9, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comAeterna Zentaris Reports Second Quarter 2023 Financial ResultsJuly 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aeterna Zentaris (AEZS) and Alnylam Pharma (ALNY)July 5, 2023 | finance.yahoo.comAeterna Zentaris to Participate in the Virtual Investor Summer Spotlight SeriesJune 14, 2023 | finance.yahoo.comAeterna Zentaris Announces Results of Virtual 2023 Meeting of ShareholdersMay 25, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Thursday (AEZS)May 24, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Tuesday (AEZS)May 5, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Friday (AEZS)April 21, 2023 | thestreet.comSpeculative Money Propels Biotechs La Jolla Pharma, Aeterna ZentarisApril 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Timber Pharmaceuticals (TMBR), Aeterna Zentaris (AEZS) and Cabaletta Bio (CABA)See More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:AEZS CUSIPN/A CIKN/A Webwww.aezsinc.com Phone18439003223FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($4.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-16,550,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.34% Return on Assets-24.19% Debt Debt-to-Equity Ratio1.53 Current Ratio8.01 Quick Ratio9.37 Sales & Book Value Annual SalesC$4.50 million Price / Sales11.62 Cash FlowC$23.47 per share Price / Cash Flow0.46 Book ValueC$3.75 per share Price / Book2.87Miscellaneous Outstanding Shares4,860,000Free FloatN/AMarket CapC$52.29 million OptionableNot Optionable Beta2.07 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNHelix BioPharmaTSE:HBPSmall PharmaCVE:DMTBriaCell TherapeuticsTSE:BCTView All Competitors AEZS Stock Analysis - Frequently Asked Questions How have AEZS shares performed in 2024? Aeterna Zentaris' stock was trading at C$2.57 at the beginning of 2024. Since then, AEZS shares have increased by 318.7% and is now trading at C$10.76. View the best growth stocks for 2024 here. How do I buy shares of Aeterna Zentaris? Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:AEZS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.